Rhumbline Advisers increased its position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) by 47.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,018 shares of the specialty pharmaceutical company’s stock after acquiring an additional 12,477 shares during the period. Rhumbline Advisers owned about 0.12% of Collegium Pharmaceutical worth $670,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of COLL. Meeder Asset Management Inc. boosted its position in Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock valued at $62,000 after buying an additional 3,179 shares in the last quarter. Jefferies Group LLC bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at $271,000. Capital Fund Management S.A. bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at $286,000. Man Group plc bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at $287,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at $339,000.
In related news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, February 15th. The shares were sold at an average price of $14.81, for a total transaction of $370,250.00. Following the completion of the transaction, the director now owns 259,430 shares of the company’s stock, valued at $3,842,158.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.87% of the stock is owned by company insiders.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The business had revenue of $73.40 million during the quarter, compared to the consensus estimate of $72.71 million. During the same quarter last year, the firm earned ($0.54) earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 579.6% on a year-over-year basis. On average, research analysts predict that Collegium Pharmaceutical Inc will post -0.14 EPS for the current fiscal year.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Cantor Fitzgerald set a $35.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, March 8th. ValuEngine raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $33.00 target price (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Wednesday, January 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $29.80.
COPYRIGHT VIOLATION NOTICE: “Rhumbline Advisers Has $670,000 Position in Collegium Pharmaceutical Inc (COLL)” was published by Markets Daily and is the property of of Markets Daily. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2019/03/18/rhumbline-advisers-has-670000-position-in-collegium-pharmaceutical-inc-coll.html.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.